Leerink Swann Raises Auxilium Pharma to Outperform (Market Perform) (AUXL)
Auxilium Pharma opened at 21.91 on Monday. Auxilium Pharma has a 1-year low of $13.59 and a 1-year high of $22.55. The company’s market cap is $1.058 billion.
Auxilium Pharma last released its earnings data on Thursday, May 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. Analysts expect that Auxilium Pharma will post $-0.06 EPS next quarter.
Several other analysts have also recently commented on the stock. Analysts at RBC Capital (NYSE: RY) raised their price target on shares of Auxilium Pharma from $26.00 to $28.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Separately, analysts at MKM Partners upgraded shares of Auxilium Pharma from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday, May 22nd. They now have a $21.00 price target on the stock, up previously from $20.00. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Auxilium Pharma in a research note to investors on Tuesday, May 22nd.
Auxilium Pharmaceuticals, Inc. ( Auxilium) is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.